11/04/2026 | Press release | Distributed by Public on 11/04/2026 16:58
|
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
|
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Restricted Stock Units | $ 0 | 11/02/2026 | J(1) | 4,603 | 02/18/2027(2) | (2) | Common Stock | 4,603 | $ 0 | 4,603 | D | ||||
| Director Stock Option (right to buy) | $19.63 | 11/02/2026 | J(1) | 37,198 | 08/17/2024 | 08/17/2033 | Common Stock | 37,198 | $ 0 | 37,198 | D | ||||
| Director Stock Option (right to buy) | $18.15 | 11/02/2026 | J(1) | 12,708 | 02/22/2025 | 02/22/2034 | Common Stock | 12,708 | $ 0 | 12,708 | D | ||||
| Director Stock Option (right to buy) | $21.77 | 11/02/2026 | J(1) | 11,236 | 02/19/2026 | 02/19/2035 | Common Stock | 11,236 | $ 0 | 11,236 | D | ||||
| Director Stock Option (right to buy) | $32.6 | 11/02/2026 | J(1) | 7,665 | 02/18/2027 | 02/18/2036 | Common Stock | 7,665 | $ 0 | 7,665 | D | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
|
Sensenig Bethany C/O SUPERNUS, INC., 9715 KEY WEST AVENUE ROCKVILLE, MD 20850 |
X | |||
| /s/ Timothy C. Dec, as attorney-in-fact | 11/04/2026 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units. |
| (2) | These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027. |